At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 839 enrolled
Drug / intervention
20vPnCbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 3, SINGLE-ARM TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHILDREN 15 MONTHS THROUGH 17 YEARS OF AGE
In Brief
A Phase 3 clinical trial evaluating 20vPnC for Pneumococcal Disease. Completed, enrolled 839 participants across 43 sites.
Detailed Summary
This study is designed to evaluate the safety and immunogenicity of 20vPnC in healthy children 15 months through 17 years of age
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumococcal Disease
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedNov 2020
Enrollment StartDec 2020
Primary CompletionApr 2022
TodayJul 2026
First PostedNov 24, 2020
Enrollment StartDec 4, 2020
Primary CompletionApr 6, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 5.6 years ago
Interventions
20vPnCbiological
20-valent pneumococcal conjugate vaccine